Tango Therapeutics (TNGX) Financials: Revenue & Earnings
TNGX$23.45+0.56 +2.42%
$3.95B
Market Cap
-26.75
P/E
18.99
Forward P/E
64
Score
Tango Therapeutics (TNGX) Financials: Revenue & Earnings
TNGX price $23.45 +0.56 +2.42%
- Ticker
- TNGX
- Price
- $23.45
- Change
- +0.56 +2.42%
- Market cap ?
- $3.95B
- P/E ?
- -26.75
- Forward P/E ?
- 18.99
- Dividend yield ?
- 0.00%
- Beta ?
- 1.17
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 64
- Value
- 45
- Quality
- 47
- Growth
- 100
Stocklytics score rationale: value 45, quality 47, growth 100.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 24649000 | 7656000 | 37042000 | 24860000 | 36527000 | 42069000 | 62384000 |
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions…
Fair value
TNGX fair value $24.78. Price $23.45. Price is 5% below fair value.
Above fair value, and more expensive than usual. A larger premium than on 92% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 10.91M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 10.73% (beta 1.2). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 168.61M. Net debt -78.71M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-03 | — | -0.35 | — | 3.28M |
| 2026-08-10 | -0.37 | -0.32 | — | 1.56M |
| 2026-05-13 | -0.32 | -0.31 | — | 578.09K |
| 2026-03-05 | -0.29 | -0.31 | — | 500.40K |
| 2025-11-04 | 0.13 | 0.01 | 53.81M | 556.00K |
| 2025-08-05 | -0.35 | -0.35 | 3.18M | 6.41M |
| 2025-05-12 | -0.36 | -0.34 | 5.39M | 6.36M |
| 2025-02-27 | -0.35 | -0.32 | 4.12M | 8.02M |
| 2024-11-06 | -0.27 | -0.34 | 11.61M | 8.02M |
| 2024-08-07 | -0.24 | -0.34 | 19.88M | 7.42M |
| 2024-05-08 | -0.35 | -0.31 | 6.47M | 6.67M |
| 2024-03-18 | -0.32 | -0.28 | 5.43M | 8.24M |
| 2023-11-08 | -0.23 | -0.34 | 10.73M | 8.62M |
| 2023-08-07 | -0.23 | -0.35 | 14.60M | 7.58M |
| 2023-05-09 | -0.32 | -0.36 | 5.77M | 6.71M |
| 2023-03-27 | -0.33 | -0.36 | 6.41M | 6.44M |
| 2022-11-10 | -0.33 | -0.32 | 6.92M | 5.64M |
| 2022-08-10 | -0.28 | -0.33 | 5.77M | 5.66M |
| 2022-05-11 | -0.29 | -0.28 | 5.76M | 5.83M |
| 2022-03-28 | -0.25 | -0.28 | 5.72M | 6.57M |
| 2021-11-09 | -0.28 | -0.28 | 6.79M | 6.26M |
| 2021-08-06 | -0.05 | — | 18.15M | — |
| 2021-07-17 | -0.14 | — | 6.39M | — |
| 2021-03-31 | -0.42 | — | 9.14M | — |
| 2020-11-13 | -0.31 | — | 11.26M | — |
| 2020-06-30 | -0.75 | — | 5.06M | — |
| 2020-03-31 | -0.74 | — | 4.71M | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Crystal Adam | Sell | 27.00K | $5.20 | 140.40K |
| 2026-10-01 | Crystal Adam | Buy | 27.00K | $5.20 | 140.40K |
| 2026-10-01 | Crystal Adam | Sell | 26.40K | $24.45 | 645.60K |
| 2026-10-01 | Crystal Adam | Sell | 600 | $25.32 | 15.19K |
| 2026-09-22 | Newcomb Jessica | Sell | 700 | $22.80 | 15.96K |
| 2026-09-22 | Newcomb Jessica | Sell | 5.10K | $23.97 | 122.24K |
| 2026-09-22 | Newcomb Jessica | Sell | 2.40K | $25.17 | 60.41K |
| 2026-09-01 | Crystal Adam | Sell | 27.00K | $5.20 | 140.40K |
| 2026-09-01 | Crystal Adam | Buy | 27.00K | $5.20 | 140.40K |
| 2026-09-01 | Crystal Adam | Sell | 27.00K | $22.37 | 603.91K |
| 2026-08-03 | Crystal Adam | Sell | 27.00K | $5.20 | 140.40K |
| 2026-08-03 | Crystal Adam | Buy | 27.00K | $5.20 | 140.40K |
| 2026-08-03 | Crystal Adam | Sell | 5.27K | $26.79 | 141.10K |
| 2026-08-03 | Crystal Adam | Sell | 21.73K | $27.35 | 594.42K |
| 2026-07-01 | Crystal Adam | Sell | 27.00K | $5.20 | 140.40K |
| 2026-07-01 | Crystal Adam | Buy | 27.00K | $5.20 | 140.40K |
| 2026-07-01 | Crystal Adam | Sell | 19.63K | $29.34 | 575.96K |
| 2026-07-01 | Crystal Adam | Sell | 7.37K | $30.25 | 222.95K |
| 2026-06-19 | Azelby Robert | Buy | 35.91K | $27.97 | 1.00M |
| 2026-06-19 | Azelby Robert | Buy | 5.74K | — | — |
| 2026-06-19 | Azelby Robert | Other | 0 | — | — |
| 2026-06-05 | Ketchum John B | Buy | 25.00K | $20.22 | 505.50K |
| 2026-06-05 | Ketchum John B | Buy | 4.00K | — | — |
| 2026-06-05 | Calhoun Lesley Ann | Buy | 25.00K | $20.22 | 505.50K |
| 2026-06-05 | Calhoun Lesley Ann | Buy | 4.00K | — | — |
| 2026-06-05 | Rothenberg Mace | Buy | 4.00K | — | — |
| 2026-06-05 | Rothenberg Mace | Buy | 25.00K | $20.22 | 505.50K |
| 2026-06-05 | Lee Sung | Buy | 570 | — | — |
| 2026-06-05 | Lee Sung | Buy | 3.57K | $20.22 | 72.19K |
| 2026-06-01 | Crystal Adam | Sell | 27.00K | $5.20 | 140.40K |
| 2026-06-01 | Crystal Adam | Buy | 27.00K | $5.20 | 140.40K |
| 2026-06-01 | Crystal Adam | Sell | 6.14K | $22.25 | 136.63K |
| 2026-06-01 | Crystal Adam | Sell | 20.86K | $23.06 | 480.94K |
| 2026-05-01 | Crystal Adam | Sell | 27.00K | $5.20 | 140.40K |
| 2026-05-01 | Crystal Adam | Buy | 27.00K | $5.20 | 140.40K |
| 2026-05-01 | Crystal Adam | Sell | 25.90K | $21.19 | 548.90K |
| 2026-05-01 | Crystal Adam | Sell | 1.10K | $22.00 | 24.20K |
| 2026-05-01 | Gall Matthew | Buy | 240.00K | $20.98 | 5.04M |
| 2026-05-01 | Gall Matthew | Buy | 40.00K | — | — |
| 2026-04-29 | Lee Sung | Buy | 12.30K | — | — |
| 2026-04-29 | Lee Sung | Buy | 5.20K | $22.06 | 114.71K |
| 2026-04-15 | Newcomb Jessica | Other | 0 | — | — |
| 2026-04-15 | Newcomb Jessica | Other | 153.09K | $11.94 | 1.83M |
| 2026-04-15 | Newcomb Jessica | Other | 130.00K | $4.26 | 553.80K |
| 2026-04-15 | Newcomb Jessica | Other | 31.42K | $5.20 | 163.37K |
| 2026-04-15 | Newcomb Jessica | Other | 2.00K | $2.67 | 5.34K |
| 2026-04-15 | Newcomb Jessica | Other | 74.30K | $12.28 | 912.34K |
| 2026-04-15 | Newcomb Jessica | Other | 10.00K | $3.13 | 31.30K |
| 2026-04-15 | Newcomb Jessica | Other | 126.19K | $2.91 | 367.21K |
| 2026-04-15 | Newcomb Jessica | Other | 1.00K | $8.93 | 8.93K |
| 2026-04-15 | Gall Matthew | Other | 0 | — | — |
| 2026-04-15 | Crystal Adam | Sell | 38.46K | $5.20 | 199.99K |
| 2026-04-15 | Crystal Adam | Buy | 38.46K | $5.20 | 199.99K |
| 2026-04-15 | Crystal Adam | Sell | 38.46K | $25.00 | 961.50K |
| 2026-04-01 | Crystal Adam | Sell | 27.00K | $5.20 | 140.40K |
| 2026-04-01 | Crystal Adam | Buy | 27.00K | $5.20 | 140.40K |
| 2026-04-01 | Crystal Adam | Sell | 27.00K | $21.20 | 572.48K |
| 2026-03-25 | Crystal Adam | Sell | 12.00K | $5.20 | 62.40K |
| 2026-03-25 | Crystal Adam | Buy | 12.00K | $5.20 | 62.40K |
| 2026-03-25 | Crystal Adam | Sell | 12.00K | $20.11 | 241.32K |
| 2026-03-05 | Crystal Adam | Sell | 20.25K | $15.00 | 303.76K |
| 2026-02-25 | Crystal Adam | Sell | 54.34K | $12.77 | 694.21K |
| 2026-02-03 | Beckman Daniella | Sell | 10.20K | $12.26 | 125.07K |
| 2026-02-03 | Beckman Daniella | Sell | 113 | $12.90 | 1.46K |
| 2026-02-03 | Weber Barbara | Sell | 30.19K | $12.26 | 370.00K |
| 2026-02-03 | Weber Barbara | Sell | 333 | $12.90 | 4.29K |
| 2026-02-03 | Crystal Adam | Sell | 18.25K | $12.26 | 223.71K |
| 2026-02-03 | Crystal Adam | Sell | 201 | $12.90 | 2.59K |
| 2026-02-02 | Beckman Daniella | Buy | 265.98K | $11.94 | 3.18M |
| 2026-02-02 | Beckman Daniella | Buy | 44.33K | — | — |
| 2026-02-02 | Weber Barbara | Buy | 37.52K | — | — |
| 2026-02-02 | Weber Barbara | Buy | 222.13K | $11.94 | 2.65M |
| 2026-02-02 | Crystal Adam | Buy | 284.76K | $11.94 | 3.40M |
| 2026-02-02 | Crystal Adam | Buy | 47.46K | — | — |
| 2026-01-08 | Peters Malte | Buy | 1.65M | $11.06 | 18.25M |
| 2026-01-08 | Peters Malte | Buy | 350.00K | — | — |
| 2026-01-02 | Lee Sung | Buy | 60.00K | $8.93 | 535.80K |
| 2026-01-02 | Lee Sung | Buy | 10.00K | — | — |
| 2026-01-02 | Lee Sung | Other | 0 | — | — |
| 2025-11-03 | Peters Malte | Buy | 150.00K | $8.01 | 1.20M |
| 2025-10-23 | Third Rock Ventures IV, L.P. | Sell | 477.40K | $10.15 | 4.85M |
| 2025-09-25 | Third Rock Ventures IV, L.P. | Sell | 500.00K | $8.02 | 4.01M |
| 2025-09-16 | Third Rock Ventures IV, L.P. | Sell | 363.54K | $7.04 | 2.56M |
| 2025-09-08 | Third Rock Ventures IV, L.P. | Sell | 86.46K | $7.04 | 608.63K |
| 2025-09-05 | Third Rock Ventures IV, L.P. | Sell | 642.91K | $7.00 | 4.50M |
| 2025-08-22 | Third Rock Ventures IV, L.P. | Sell | 302.19K | $7.00 | 2.12M |
| 2025-08-19 | Third Rock Ventures IV, L.P. | Sell | 1.10M | $7.01 | 7.71M |
| 2025-06-05 | Peters Malte | Buy | 37.50K | $3.51 | 131.62K |
| 2025-06-05 | Peters Malte | Buy | 6.25K | — | — |
| 2025-06-05 | Calhoun Lesley Ann | Buy | 37.50K | $3.51 | 131.62K |
| 2025-06-05 | Calhoun Lesley Ann | Buy | 6.25K | — | — |
| 2025-06-05 | Rothenberg Mace | Buy | 37.50K | $3.51 | 131.62K |
| 2025-06-05 | Rothenberg Mace | Buy | 6.25K | — | — |
| 2025-06-05 | Ketchum John B | Buy | 37.50K | $3.51 | 131.62K |
| 2025-06-05 | Ketchum John B | Buy | 6.25K | — | — |
| 2025-06-05 | Borisy Alexis | Buy | 37.50K | $3.51 | 131.62K |
| 2025-06-05 | Borisy Alexis | Buy | 6.25K | — | — |
| 2025-02-05 | Barry Douglas | Sell | 2.56K | $3.16 | 8.08K |
| 2025-02-05 | Beckman Daniella | Sell | 3.95K | $3.16 | 12.48K |
| 2025-02-05 | Crystal Adam | Sell | 6.85K | $3.16 | 21.66K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 259, holders +61 vs prior quarter. Ownership 143.40%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 13.90M | 600.00K | +4.51% | 434.53M |
| BLACKROCK, INC. | 12.44M | 3.69M | +42.19% | 388.83M |
| FMR LLC | 12.33M | 2.43M | +24.50% | 385.54M |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 12.28M | 3.18M | +34.95% | 383.78M |
| BOXER CAPITAL MANAGEMENT, LLC | 10.88M | 0 | 0.00% | 339.99M |
| GOLDMAN SACHS GROUP INC | 9.98M | 4.90M | +96.61% | 311.99M |
| TCG CROSSOVER MANAGEMENT, LLC | 9.08M | -1.45M | -13.77% | 283.88M |
| PARADIGM BIOCAPITAL ADVISORS LP | 6.36M | 2.35M | +58.55% | 198.74M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.35M | 5.46M | +613.83% | 198.47M |
| SIREN, L.L.C. | 6.18M | 522.26K | +9.23% | 193.17M |
| STATE STREET CORP | 5.98M | 1.33M | +28.55% | 186.93M |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.96M | 795.92K | +15.42% | 186.23M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.60M | -7.21M | -56.28% | 175.06M |
| JUPITER TOPCO LLC | 5.06M | 5.06M | New | 157.99M |
| DEEP TRACK CAPITAL, LP | 4.20M | 1.45M | +52.73% | 131.29M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4.19M | 43.80K | +1.06% | 131.00M |
| WOODLINE PARTNERS LP | 4.00M | -4.00M | -49.99% | 125.06M |
| TRV GP IV, LLC | 6.37M | 0 | 0.00% | 120.18M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.74M | 1.07M | +39.88% | 117.02M |
| PERCEPTIVE ADVISORS LLC | 3.38M | 2.57M | +317.87% | 105.57M |
| SEVEN FLEET CAPITAL MANAGEMENT LP | 3.23M | 2.73M | +543.04% | 95.66M |
| LOGOS GLOBAL MANAGEMENT LP | 2.85M | -150.00K | -5.00% | 89.09M |
| CALIGAN PARTNERS LP | 2.50M | 91.31K | +3.79% | 78.15M |
| HOLOCENE ADVISORS, LP | 2.41M | -1.52M | -38.69% | 75.37M |
| COMMODORE CAPITAL LP | 2.25M | 2.25M | New | 70.33M |
Earnings and financials
Tango Therapeutics, Inc. (TNGX) trades at $23.45, with a market cap of $3.95B and a trailing P/E of -26.75. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 24649000 | 7656000 | 37042000 | 24860000 | 36527000 | 42069000 | 62384000 |
Insights · Dividends · Forecast · Financials · Learn